Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Animals Antineoplastic Combined Chemotherapy Protocols / pharmacology Apoptosis Biomarkers, Tumor / antagonists & inhibitors Breast Neoplasms / drug therapy Cell Proliferation Colorectal Neoplasms / drug therapy Cyclin-Dependent Kinase 4 / antagonists & inhibitors Cyclin-Dependent Kinase 6 / antagonists & inhibitors Esophageal Neoplasms / drug therapy Everolimus / administration & dosage Female Gene Expression Regulation, Neoplastic / drug effects Humans MAP Kinase Kinase 1 / antagonists & inhibitors Mice Mice, Inbred NOD Mice, Nude Mice, SCID Piperazines / administration & dosage Protein Kinase Inhibitors / pharmacology Pyrazoles / administration & dosage Pyridines / administration & dosage Pyridones / administration & dosage Pyrimidines / administration & dosage Pyrimidinones / administration & dosage Quinolines / administration & dosage Receptor, ErbB-2 / metabolism TOR Serine-Threonine Kinases / antagonists & inhibitors Tumor Cells, Cultured Xenograft Model Antitumor Assays

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 12 08 2020
revised: 16 10 2020
accepted: 23 12 2020
pubmed: 9 1 2021
medline: 8 2 2022
entrez: 8 1 2021
Statut: ppublish

Résumé

Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA approved for HER2-overexpressing/amplified (HER2 Cell viability, colony formation assays, and Western blotting were used to determine the effect of neratinib In HER2 Taken together, our results provide strong preclinical evidence for combining neratinib with CDK4/6, mTOR, and MEK inhibitors for the treatment of HER2

Identifiants

DOI: 10.1158/1078-0432.CCR-20-3017 PMID: 33414137 PMC: PMC8075007
pubmed: 33414137
pii: 1078-0432.CCR-20-3017
doi: 10.1158/1078-0432.CCR-20-3017
pmc: PMC8075007
mid: NIHMS1659035
doi:

Substances chimiques

Biomarkers, Tumor 0
Piperazines 0
Protein Kinase Inhibitors 0
Pyrazoles 0
Pyridines 0
Pyridones 0
Pyrimidines 0
Pyrimidinones 0
Quinolines 0
trametinib 33E86K87QN
Everolimus 9HW64Q8G6G
MTOR protein, human EC 2.7.1.1
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
TOR Serine-Threonine Kinases EC 2.7.11.1
CDK4 protein, human EC 2.7.11.22
CDK6 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 4 EC 2.7.11.22
Cyclin-Dependent Kinase 6 EC 2.7.11.22
MAP Kinase Kinase 1 EC 2.7.12.2
MAP2K1 protein, human EC 2.7.12.2
palbociclib G9ZF61LE7G
sapanisertib JGH0DF1U03
neratinib JJH94R3PWB

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1681-1694

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224065
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Cell Death Dis. 2019 Apr 24;10(5):342
pubmed: 31019203
Cancer Cell. 2018 Nov 12;34(5):792-806.e5
pubmed: 30449325
J Natl Compr Canc Netw. 2017 Mar;15(3):370-398
pubmed: 28275037
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Ann Oncol. 2013 Jan;24(1):109-16
pubmed: 22967996
Cell Death Dis. 2018 Jul 24;9(8):810
pubmed: 30042422
Cancer Cell. 2009 May 5;15(5):429-40
pubmed: 19411071
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956
Antimicrob Agents Chemother. 2004 Oct;48(10):3702-10
pubmed: 15388423
PLoS One. 2015 Oct 16;10(10):e0140652
pubmed: 26473483
Trends Cell Biol. 2006 Dec;16(12):649-56
pubmed: 17085050
Cancer Discov. 2017 Jun;7(6):575-585
pubmed: 28274957
J Clin Oncol. 2018 May 1;36(13):1308-1316
pubmed: 29543566
Sci Signal. 2014 Mar 25;7(318):ra29
pubmed: 24667376
J Med Chem. 2005 Feb 24;48(4):1107-31
pubmed: 15715478
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Clin Cancer Res. 2020 Nov 15;26(22):5820-5829
pubmed: 32938620
J Cell Commun Signal. 2019 Sep;13(3):357-368
pubmed: 30848427
Oncogene. 2007 Oct 4;26(45):6469-87
pubmed: 17471238
BMC Neurosci. 2006 Jun 15;7:49
pubmed: 16776830
Clin Cancer Res. 2017 Nov 1;23(21):6468-6477
pubmed: 29093017
Breast Cancer Res. 2019 Jul 5;21(1):78
pubmed: 31277699
Breast Cancer Res. 2017 Aug 15;19(1):93
pubmed: 28810913
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
pubmed: 16829981
Breast Cancer Res Treat. 2011 Jan;125(2):447-55
pubmed: 21107682
Future Med Chem. 2020 Apr;12(7):563-565
pubmed: 32083493
Oncogene. 2014 Feb 27;33(9):1073-81
pubmed: 23542173
Cancer Discov. 2015 Aug;5(8):832-41
pubmed: 26243863
Cancer Res. 2013 Jul 1;73(13):3817-20
pubmed: 23794708
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972
pubmed: 27407089
J Clin Oncol. 2011 Aug 10;29(23):3126-32
pubmed: 21730275
Curr Med Chem. 2012;19(7):1065-75
pubmed: 22229414
PLoS One. 2017 May 2;12(5):e0176778
pubmed: 28463969
Cancer Res. 2008 Aug 1;68(15):6084-91
pubmed: 18676830
Cancer Discov. 2020 Feb;10(2):198-213
pubmed: 31806627
Stem Cells. 1998;16(6):413-28
pubmed: 9831867
Biochem Pharmacol. 2019 May;163:133-141
pubmed: 30772267
Lancet Oncol. 2017 Jun;18(6):743-754
pubmed: 28526538
Cancer Chemother Pharmacol. 2013 Nov;72(5):1089-96
pubmed: 24057042
Cancer Res. 2004 Jun 1;64(11):3958-65
pubmed: 15173008
Endocrinology. 2004 Oct;145(10):4677-84
pubmed: 15208212
Arch Pharm (Weinheim). 2008 Aug;341(8):465-77
pubmed: 18493974
Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57
pubmed: 27284682
N Engl J Med. 2016 Jul 7;375(1):11-22
pubmed: 27406346
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Mol Biol Cell. 2008 Mar;19(3):1185-98
pubmed: 18172021
Lancet Oncol. 2015 Jul;16(7):816-29
pubmed: 26092818
Cancer Res. 2008 Nov 15;68(22):9221-30
pubmed: 19010894
Breast Cancer (Dove Med Press). 2015 Jun 09;7:147-62
pubmed: 26089701
J Clin Oncol. 2014 Jan 10;32(2):68-75
pubmed: 24323026
Cancer Res. 2005 Apr 1;65(7):2554-9
pubmed: 15805248
Oncogene. 2004 Apr 12;23(16):2797-808
pubmed: 15077143
ESMO Open. 2018 Jan 10;3(1):e000299
pubmed: 29387480
PLoS One. 2015 Sep 01;10(9):e0136851
pubmed: 26325287
J Clin Oncol. 2014 Nov 10;32(32):3626-33
pubmed: 25287822
Clin Cancer Res. 2012 Mar 15;18(6):1777-89
pubmed: 22422409
Int J Mol Med. 2013 Apr;31(4):904-12
pubmed: 23426850
Clin Cancer Res. 2017 Nov 15;23(22):7006-7019
pubmed: 28821558
Antioxid Redox Signal. 2013 Aug 20;19(6):559-71
pubmed: 23025416

Auteurs

Ming Zhao (M)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Stephen Scott (S)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kurt W Evans (KW)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Erkan Yuca (E)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Turcin Saridogan (T)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Xiaofeng Zheng (X)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Heping Wang (H)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Anil Korkut (A)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Christian X Cruz Pico (CX)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
ORCID: 0000-0002-5620-7727

Mehmet Demirhan (M)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Bryce Kirby (B)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Scott Kopetz (S)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Irmina Diala (I)

Puma Biotechnology Inc, Los Angeles, California.

Alshad S Lalani (AS)

Puma Biotechnology Inc, Los Angeles, California.

Sarina Piha-Paul (S)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funda Meric-Bernstam (F)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. fmeric@mdanderson.org.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Proline-directed protein kinases › Kinases cyclines-dépendantes › Kinase-4 cycline-dépendante › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Proline-directed protein kinases › Kinases cyclines-dépendantes › Kinase-6 cycline-dépendante › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › Tumeurs de l'oesophage › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés chimiques organiques › Lactones › Sirolimus › Évérolimus › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Mitogen-Activated Protein Kinase Kinases › MAP Kinase Kinase 1 › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée NOD › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris SCID › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Pyridones › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Sérine-thréonine kinases TOR › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Combining Neratinib with CDK4/6, mTOR, and MEK...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Combining Neratinib with CDK4/6, mTOR, and MEK...